NORTENOLOL

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

ATENOLOL

Available from:

Tillomed Laboratories Limited

ATC code:

C07AB03

INN (International Name):

ATENOLOL

Dosage:

50 Milligram

Pharmaceutical form:

Film Coated Tablet

Prescription type:

Product subject to prescription which may be renewed (B)

Therapeutic area:

atenolol

Authorization status:

Marketed

Authorization date:

1999-05-27

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
NORTENOLOL 25MG, 50MG AND 100MG FILM-COATED TABLETS
(ATENOLOL)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1. What Nortenolol is and what it is used for
2. What you need to know before you take Nortenolol
3. How to take Nortenolol
4. Possible side effects
5. How to store Nortenolol
6. Contents of the pack and other information
1. WHAT NORTENOLOL IS AND WHAT IT IS USED FOR
The active ingredient in Nortenolol is ATENOLOL which belongs to a
group of medicines called
beta−blockers, which help slow the heartbeat and relax the blood
vessels. This reduces blood pressure
and the heart’s demand for oxygen.
Nortenolol is used to treat the following conditions:

HIGH BLOOD PRESSURE (hypertension)

CHEST PAIN (angina pectoris): Nortenolol helps to prevent or reduce
chest pains which may occur
when your heart cannot get enough oxygen, such as when doing exercise

IRREGULAR HEARTBEAT (cardiac dysrhythmias): Nortenolol helps to
control abnormal heart beats, by
slowing the heart rate

PROTECT THE HEART IN THE EARLY TREATMENT AFTER A HEART ATTACK
(myocardial infarction):
Nortenolol helps to reduce the damage to the heart if taken shortly
after a heart attack and
decrease the risk of continued illness
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE NORTENOLOL
DO NOT TAKE NORTENOLOL IF:

You are allergic (hypersensitive) to Atenolol, other beta-blockers or
any of the other ingredients
of this medicine (listed in section 6)

You have heart problems su

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Nortenolol 50mg Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains atenolol 50 mg
Excipients with known effect: Each tablet contains 95 mg lactose
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film coated tablets
White to off-white, biconvex, film-coated unscored tablet marked
‘A50’.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Management of hypertension.
Management of angina pectoris.
Management of cardiac dysrhythmias.
Myocardial infarction - early intervention in the acute phase.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_POSOLOGY_
_Hypertension:_
The usual dose is one 100 mg tablet daily. Some patients may respond
to a dose of one 50 mg tablet daily. The
therapeutic effect is fully established after administration for one
to two weeks. Further reduction in blood pressure, if
desired, can be achieved by combining atenolol with other
antihypertensive agents.
_Angina pectoris:_
One 100 mg tablet once daily or one 50 mg tablet twice daily are
taken. Additional benefit is unlikely to be gained by
increasing the dose.
_Cardiac dysrhythmias:_
Having controlled the dysrhythmia with intravenous atenolol the
maintenance oral dose is one 50 mg tablet to one 100
mg tablet daily as a single dose.
_Myocardial infarction:_
Patients presenting within 12 hours of the onset of chest pains and
suitable for beta blockade therapy: 5 to 10 mg of
Atenolol is administered by slow intravenous injection (1 mg/minute).
If no adverse effects occur following the intravenous dose, then 15
minutes later one 50 mg tablet is administered orally
followed by a further 50 mg tablet, 12 hours after the intravenous
dose. Then 12 hours later one 100 mg tablet is given
orally, once daily. If bradycardia and/or hypertension requiring
treatment, or any other side effects, occur atenolol
therapy should be discontinued.
_Elderly patients:_
Dosage requirements may be reduced, especially in those with impaired
renal func